The growing prevalence of target disease prevalence and increasing adoption of stem cell therapies for chronic disease treatment is driving the market growth.
The global Stem Cells market size is estimated to reach USD 17.78 billion from USD 9.35 billion in 2019, delivering a CAGR of 8.4% through 2027. The market growth is driven by the huge success of regenerative medicine and an exponential rise in stem cell-based research activities.
Stem cell offers several benefits over many surgical options as it stimulates the natural healing response by utilizing the cells sourced from the same patient instead of artificial implants or a prosthetic replacement. It also eliminates the need for surgery as well as any post-treatment complications or risks associated with surgery.
Positive government initiatives supporting stem cell banking is several countries across the globe will boost the market growth. In addition, rise in the number of stem cell banks, especially across the developing nations, will supplement stem cells market share over the coming years.
Rising outbreaks of infections have led to the development of vaccines using different non-tumorigenic cell lines and human diploids. The rise in ongoing R&D for the development of vaccines against various chronic diseases will foster stem cells market revenue share through 2027.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2981
Key participants contributing to the global stem cells market share include
Celgene Corporation, ReNeuron Group plc, Virgin Health Bank, Biovault Family, Mesoblast Ltd., Caladrius, Opexa Therapeutics, Inc., Precious Cells International Ltd., Pluristem, and Neuralstem, Inc., among others.
Increasing development of on-demand, digitally enabled, and seamlessly connected clinician-patient interactions to manage patient base is expected to drive pharma and healthcare market in the coming years. After the COVID-19 outbreak there has been a number of foundational shifts in the healthcare system. Some of the examples include increasing consumer involvement in health care decision-making, the rapid adoption of virtual health & other digital innovations, increasing focus on utilization of interoperable data & data analytics, and increased public-private collaborations in therapeutics and vaccine development. The increased public-private collaborations for vaccine development has arisen due to high pressure of regional governments. Health care providers, and other stakeholders have invested heavily to quickly pivot, adapt, and innovate therapeutics.
Surging demands and transition to patient-centric care delivery across geographies will change pharma and healthcare market trends through 2027.
The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and Machine Learning to enhance efficiency of medical products. Top companies in the market are focusing on R&D activities to expand their product offerings and cater to unmet medical needs.
This report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, and recent developments in both historic and present contexts.
Further key findings from the report suggest
The growing prevalence of cancer and an exponential demand for effective management and treatment of the disease is driving stem cells market growth.
According to the WHO, there were nearly 18.1 million new cases and 9.6 million deaths in 2018. Cancer Research UK estimates that there will be approximately 27.5 million new cases each year across the globe by 2040.
On the basis of product type, the induced pluripotent stem cells segment is estimated to register the maximum growth rate through 2027 due to its potential to significantly advance drug development & clinical research.
Based on therapy outlook, the autologous stem cell therapy segment is forecast to exhibit a growth rate of 8.6% over the analysis period. The robust growth can be attributed to the low risk of complications associated with this treatment. Moreover, the improved survival rate of patients, no need for identification of an HLA-matched donor, affordability, as well as no risk of graft-versus-host diseases are some of the factors leading to the popularity of the autologous stem cell therapy.
Based on application, the regenerative medicine segment is poised to showcase a CAGR of 8.5% through 2027 on account of the development of cutting-edge orthopedic treatments involving stem cell therapy, which enable boosting recovery time, pain relief, increases mobility, and eliminates the need for invasive surgery such as joint replacements, or any kind of medications.
North America accounted for the majority of the stem cells market share in 2019 and is set to contribute significantly to the market revenue share through 2027 due to high R&D investments in cytological research in the region. Additionally, increased preference for stem cell therapies, advanced healthcare infrastructure, and strong reimbursement framework are some other factors bolstering regional industry growth.
Europe is anticipated to witness a growth rate of 8.5% over the projected timeframe.
The Asia Pacific region is expected to hold 22% of the global stem cells market share by 2027 due to several product pipelines in cell-based therapies and a large patient population.
In 2018, Kineta Immuno-Oncology, LLC, a subsidiary of Kineta Inc, a clinical-stage biotechnology company, entered into a research collaboration & license agreement with Pfizer Inc. to develop RIG-I agonist immunotherapies for the treatment of cancer.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2981
For the purpose of this report, Reports and Data has segmented into the global Stem Cells market on the basis of product, technology, therapy, application, and region:
Product Outlook (Revenue, USD Billion; 2017-2027)
Adult stem cells
Neuronal stem cells
Mesenchymal stem cells
Hematopoietic stem cells
Umbilical cord stem cells
Adiposeâ€derived stem cells
Dental stem cells
Dedifferentiated fat (DFAT) cells
Other adult-derived stem cells
Human embryonic stem cells
Very small embryonic like stem cells
Technology Outlook (Revenue, USD Billion; 2017-2027)
Umbilical cord blood
Bone marrow harvest
Expansion and sub-culture
Therapy Outlook (Revenue, USD Billion; 2017-2027)
Allogenic Stem Cell Therapy
Autologous Stem Cell Therapy
Application Outlook (Revenue, USD Billion; 2017-2027)
Hematology stem cells
Soft tissue injuries
Cardiovascular and myocardial infarction-based
Drug discovery & development
Regional Outlook (Revenue, USD Billion; 2017-2027)
Middle East & Africa
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2981
Thank you for reading our report. To know more about the customization feature, please get in touch with us and our team will ensure the report is customized as per your requirements.
Read More Reports:-
Analytical Standards Market @ https://www.google.kz/url?q=https://www.reportsanddata.com/report-detail/analytical-standards-market
Predictive Genetic Testing & Consumer/Wellness Genomics Market @ https://www.google.me/url?q=https://www.reportsanddata.com/report-detail/predictive-genetic-testing-and-consumer-wellness-genomics-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370